clinical trial · NCT04677972
SPI-1005 for the Treatment of Meniere's Disease
Sound Pharmaceuticals, Incorporated·phase3·completed·n = 254
Meniere DiseaseMénièreEbselenPlacebo
brief summary
The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite Meniere's disease with active symptoms within three months preceding study enrollment.
started
Aug 2, 2022
primary completion
Sep 19, 2023
completion
Jul 25, 2024
last updated
Aug 1, 2024
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol